TRT and Fertility: What Men Should Know Before Starting

Testosterone replacement therapy solves one problem and creates another for men who still want to have children. Exogenous testosterone signals the brain to shut down its own hormone production, which includes the signals the testes need to make sperm. The result: azoospermia (zero sperm count) in roughly 40% of men on TRT, and reduced sperm production in many more. That's not a minor side effect for a man trying to conceive with a partner — but it's also not an all-or-nothing choice between TRT and fertility, which is where the research on adjunct therapies comes in. Why TRT Shuts Down Fertility The testes don't just respond to testosterone — they need a specific signal from the pituitary gland (luteinizing hormone, or LH) to keep producing testosterone locally, at concentrations far higher than what circulates in blood. That local, intratesticular testosterone is what actually drives sperm production. When TRT raises blood testosterone, the brain senses "enough hormone" and stops sending LH, which causes intratesticular testosterone to collapse even while blood levels look great on a lab report. Sperm production depends on that local concentration, not the blood number — which is exactly why a man can have a "great" testosterone level on TRT and still be azoospermic. hCG: The Most-Studied Fertility-Preserving Option Human chorionic gonadotropin (hCG) mimics LH directly, stimulating the testes to keep producing testosterone locally even while TRT suppresses the body's own LH signal. This is the best-researched approach to preserving fertility during TRT, and multiple studies point the same direction. One study of 26 men on TRT who were also given concurrent low-dose hCG found it maintained semen parameters and was associated with preserved fertility, describing hCG as protective for continued spermatogenesis alongside TRT. Follow-up research examining different hCG dosing schedules found intratesticular testosterone was maintained across all tested doses, with levels closest to normal at the higher end of the studied dose range — supporting the idea that hCG, at a low but consistent dose alongside TRT, can prevent the drop in local testosterone that otherwise shuts down sperm production. hCG is FDA-approved for stimulating testicular testosterone production, though research notes that spermatogenesis isn't fully maintained long-term on hCG alone without FSH support. Restoring Fertility After TRT: hCG Plus FSH For men already on TRT with impaired fertility who want to actively restore sperm production (rather than just maintain it going forward), research has looked at combining hCG with FSH (follicle-stimulating hormone) — the other pituitary signal needed for sperm production, which hCG alone doesn't fully replace. The largest retrospective study on this approach followed 77 men with a history of testosterone use who were treated with combined hCG and FSH therapy. The results were substantial: 74% of men showed improved sperm concentration, with mean levels rising from 2.2 million/mL to 15.2 million/mL over an average of 7 months of treatment. Among men who started completely azoospermic, roughly 65% saw sperm return, and more than half of men starting with severe low counts reached normal sperm concentrations. The most clinically useful finding from that study, for men who don't want to stop TRT entirely: roughly a third of the cohort stayed on concurrent testosterone therapy throughout the hCG/FSH treatment, and their improvement in sperm concentration was statistically no different from the men who came off TRT completely. In the researchers' own words, concurrent testosterone therapy did not impede hCG/FSH-mediated recovery of spermatogenesis. That's a meaningfully different picture than the older, simpler advice of "stop TRT and wait." Enclomiphene: A Different Approach Entirely A separate strategy skips exogenous testosterone altogether. Enclomiphene citrate, the purified active isomer of clomiphene, blocks estrogen receptors in the hypothalamus, which the brain interprets as low estrogen and responds to by increasing its own LH and FSH output — raising natural testosterone production while preserving the pituitary signals sperm production depends on. Research describes clomiphene-based approaches as showing efficacy comparable to TRT for symptom improvement (energy, libido, mood), with the meaningful advantage of not suppressing fertility in the first place, though it comes with its own distinct side effect profile including possible gynecomastia, mood changes, and in rare cases visual disturbances. For men who haven't started TRT yet and are specifically concerned about fertility, this represents a genuinely different path: treating low testosterone symptoms without ever inducing the suppression that makes hCG/FSH "reboot" therapy necessary in the first place. What This Means in Practice The research supports a few clear conclusions: TRT alone, without any adjunct therapy, frequently suppresses fertility and can cause azoospermia. Concurrent low-dose hCG appears to meaningfully protect against that suppression in men who want to stay on TRT while preserving fertility. For men already experiencing fertility problems from prior or current TRT use, combined hCG/FSH therapy has real, substantial evidence behind it for restoring sperm production — and importantly, doesn't require stopping testosterone therapy to work. And for men who haven't started TRT yet, enclomiphene is a legitimate alternative worth discussing with a physician specifically because it raises testosterone without suppressing the fertility axis at all. None of this is a do-it-yourself protocol — hCG, FSH, and enclomiphene all require prescription, monitoring, and dosing individualized to bloodwork and semen analysis, which is exactly the kind of decision that belongs in a conversation with a urologist or reproductive endocrinologist rather than a fixed formula. But the larger point is worth taking away on its own: a TRT diagnosis doesn't have to mean choosing between treating low testosterone and having children. The research increasingly supports that you often don't have to choose.